GGrantIndex
← Search

Core--Cell Resources- Shared Resource

$46,244P30FY2007CANIH

Wayne State University, Detroit MI

Investigators

Linked publications, trials & patents

Trial NCT06501040Trial NCT04479267Trial NCT04397679Trial NCT04266522Trial NCT04159896Trial NCT03875053Trial NCT03683420Trial NCT03456804Trial NCT03454529Trial NCT03453489Trial NCT03406858Trial NCT03252600Trial NCT03147885Trial NCT02824029Trial NCT02819024Trial NCT02723604Trial NCT02620865Trial NCT02568449Trial NCT02521090Trial NCT02520115Trial NCT02472275Trial NCT02470559Trial NCT02359019Trial NCT02178436Trial NCT02178163Trial NCT02173093Trial NCT02145078Trial NCT02094872Trial NCT02058706Trial NCT02037256Trial NCT01987596Trial NCT01958372Trial NCT01698658Trial NCT01504711Trial NCT01281163Trial NCT01175980Trial NCT01147016Trial NCT01116232Trial NCT01071564Trial NCT01051570Trial NCT01022138Trial NCT00984919Trial NCT00972023Trial NCT00942422Trial NCT00938626Trial NCT00935090Trial NCT00918762Trial NCT00914147Trial NCT00906503Trial NCT00903214Trial NCT00899665Trial NCT00897910Trial NCT00897741Trial NCT00897494Trial NCT00897247Trial NCT00890617Trial NCT00888654Trial NCT00769288Trial NCT00768118Trial NCT00717535Trial NCT00691015Trial NCT00559897Trial NCT00541099Trial NCT00527124Trial NCT00521261Trial NCT00520767Trial NCT00514215Trial NCT00503841Trial NCT00499694Trial NCT00482846Trial NCT00459121Trial NCT00438204Trial NCT00423826Trial NCT00410904Trial NCT00376948Trial NCT00369109Trial NCT00305747Trial NCT00303901Trial NCT00301808Trial NCT00293384Trial NCT00288028Trial NCT00258466Trial NCT00258310Trial NCT00258284Trial NCT00258245Trial NCT00258232Trial NCT00248560Trial NCT00248482Trial NCT00244946Trial NCT00244933Trial NCT00243048Trial NCT00238329Trial NCT00227721Trial NCT00217581Trial NCT00121264Trial NCT00118157Trial NCT00078923Trial NCT00068653Trial NCT00066326Trial NCT00056004

Abstract

The Cell Resources Core (CRC) provides KCI members, and national and international cancer researchers, access to cell resources, most of which are unique and many of which are important to cancer research, as well as to services that enhance accomplishment of their cancer research. Originally established to provide iinvestigators the estrogen-responsive MCF-7 human breast cancer cell line and MCF10-A/F non-tumorigenic human breast epithelial cell lines, the scope of resources has expanded through the expertise of the current staff. New unique resources include a spectrum of MCF-10A derivatives with phenotypes in xenografts including preneoplasia by MCF-10AT, weak tumorigenicity by MCF-10AT1, carcinoma in situ by DCIS.com, and highly tumorigenic and metastatic MCF-10CA1a and CA1d cell lines. These lines constitute isogenic cells to examine breast neoplasia. Additionally, mortal fibroblast and epithelial cells and cell lines are available that were derived from human and mouse tissues including reduction mammoplasty and benign breast tissues, and human bile duct tumors. Services available include scientific consultation and assistance with development of new cell resources, toxicity testing for microchip gene expression analyses, clonogenic assays testing therapeutic response, and establishment of cultures from breast tissues. Benefits to Cancer Center Members include unique and reliable resources, the ability to develop new and unique resources, and the availability of specialized services. Also, the KCI benefits from stimulation of scientific interactions.

View original record on NIH RePORTER →